Halozyme Therapeutics Inc (HALO)

[OncoJock]

Just picked up a few more shares when the price dipped below $55.

FYI, the following buy/sell ratings are held on Halo by the following agencies, as of the following dates:

Schwab: "A" rating (outperform, highest rating), as of 1/4/23

Reuters: Outperform (2nd from highest rating), 12/24/22

CFRA: Hold (middle of 5 ratings), 12/30/22

FYI, CFRA graded HALO poorly on the dimension of "growth," which is one of 6 factors that go into the overall "Hold" rating. CFRA rated the company's growth prospects as "negative." The report explains that "growth" includes factors such as EPS growth and stability and cash flow growth and stability.

A chart included in the report shows the company's 1-year compound annual growth rate (CAGR) for EPS to be -47.0%, compared to 6.4% for its peer group and 7.0% for the S&P 500. I'm guessing this may have to do with some arithmetic calculations that got thrown off by the Antares acquisition. There seems to be some wild fluctuations, since the corresponding figures for the 3-year %CAGR are 109%, 13.5%, and 12.1% for the company, its peers, and the S&P 500 index, respectively. Maybe this is what CFRA means by lack of stability?

If anyone on this board, such as MauMar or Fred Kadiddlehopper, cares to comment, I'd be quite interested in your views.

Happy New Year to all.